Keywords: Myelofibrosis; Allogeneic stem cell transplantation; Molecular genetics; Calreticulin; ASXL1;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ASXL1; additional sex combs like 1; BCOR; BCL6 corepressor; BRAF; v-Raf murine sarcoma viral oncogene homolog B; CEBPA; CCAAT/enhancer binding protein alpha; DNMT3A; DNA methyltransferase 3A; FLT3; fms-like tyrosine kinase; IDH1/2; isocitrate dehydrogenas
Keywords: α-KG; alpha-ketoglutarate; 2-HG; 2-hydroxyglutarate; 5hmC; 5-hydroxymethylcytosine; 5mC; 5-methylcytosine; AML; acute myeloid leukemia; ASXL1; additional sex combs-like 1; AZA; azacytidine; CMML; chronic myelomonocytic leukemia; DAC; decitabine; DNMT3A;
Keywords: 4-HPR; N-(4-hydroxyphenyl)retinamide; 5â²-UTR; 5â²-untranslated region; 9-cis-RA; 9-cis retinoic acid; 9cUAB30; (2E,4E,6Z,8E)-8-(3â²,4â²-dihydro-1â²(2'H)-naphthalen-1â²-ylidene)-3,7-dimethyl-2,4,6-octatrienoic acid; Acitretin; (2E,4E,6E,8E)-9-(4-met
Keywords: ASXL1; BAP1; CREBBP; DNMT3A; EP300; EZH2
Keywords: Systemic mastocytosis; KIT; Mutation; Signaling; TET2; ASXL1; Spliceosome; Targeted therapy;
Double sword role of EZH2 in leukemia
Keywords: EZH1,2; enhancer of Zeste 1 and 2; SUZ12; suppressor of zeste 12 homolog; EED; embryonic ectoderm development; AEBP2; adipocyte enhancer-binding protein 2; RBAP46/48; retinoblastoma binding proteins 46 and 48; PRC; polycomb-repressive complex; PcG; Polyco
Epigenetics in myelodysplastic syndromes
Keywords: MDS; Epigenetics; ASXL1; DNMT3A; EP300; EZH2; IDH1; IDH2; KDM2B; KDM5A; KDM6A; MLL; MLL2; MLL3; MLL5; TET2; WT1; Hypomethylating agent; HDAC inhibitor;
Research paperPrimary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease
Keywords: Myelofibrosis; C-reactive protein; Inflammation; JAK2V617F; MPL; CALR; ASXL1; EZH2; A3669G polymorphism; 46/1 haplotype;
Transformation of the Clinical Management of CMML Patients Through In-Depth Molecular Characterization
Keywords: ASXL1; Chronic myelomonocytic leukemia; Hypomethylating agent; Next-generation sequencing; TET2;
BAP1 regulates cell cycle progression through E2F1 target genes and mediates transcriptional silencing via H2A monoubiquitination in uveal melanoma cells
Keywords: ASXL1; additional sex combs-like 1; BAP1; BRCA1 associated protein-1; BRCA1; breast cancer gene 1; CSC; cancer stem cells (CSC); DTB; double thymidine block; DUB; deubiquitinating enzyme; E2F1; E2F transcription factor 1; FOXK; the forkhead transcription
Reciprocal regulation of LXRα activity by ASXL1 and ASXL2 in lipogenesis
Keywords: ASXL; additional sex comb-like; LXRα; liver X receptor alpha; WB; Western blotting; Luc; luciferase; shRNA; small hairpin RNA; KD; knockdown; ChIP; chromatin immunoprecitation; HFD; high fat diet; Liver X receptor; ASXL1; ASXL2; Lipogenesis; Liver;
Anomalies moléculaires au cours des mastocytoses : conséquences pronostiques et thérapeutiques
Keywords: Mastocytose systémique; Mutation; KIT; TET2; ASXL1; SRSF2; Thérapies cibléesSystemic mastocytosis; Genetic mutations; KIT; TET2; ASXL1; SRSF2; Prognosis; Therapy
Role of TET2 and ASXL1 Mutations in the Pathogenesis of Myeloproliferative Neoplasms
Keywords: ASXL1; TET2; Myelofibrosis; Myeloproliferative neoplasms; JAK2;
Actualités 2011 sur la physiopathologie des syndromes myéloprolifératifs classiques hors LMC (polyglobulie de Vaquez, thrombocytémie essentielle et myélofibrose primaire)
Keywords: SMP : syndrome myéloprolifératif; PV : polyglobulie de Vaquez; TE : thrombocytémie essentielle; MPF : myélofibrose primaire; JAK2 : Janus activated kinase 2; MPL : myeloproliferative leukemia (récepteur de la thrombopoiétine); TET2 : Ten eleven tran
Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations
Keywords: RARS-T; TET2; ASXL1; JAK2 V617F; MPL W515L; STAT5